WallStreetZenWallStreetZen

NASDAQ: TARS
Tarsus Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for TARS

Based on 5 analysts offering 12 month price targets for Tarsus Pharmaceuticals Inc

Min Forecast
$88.00+21.05%
Avg Forecast
$93.00+27.92%
Max Forecast
$100.00+37.55%

Should I buy or sell TARS stock?

Based on 5 analysts offering ratings for Tarsus Pharmaceuticals Inc.

Strong Buy
Strong Buy
2 analysts 40%
Buy
3 analysts 60%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although TARS's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates TARS as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their TARS stock forecasts and price targets.

TARS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-08-12
lockedlocked$00.00+00.00%2026-07-31
lockedlocked$00.00+00.00%2026-07-21
lockedlocked$00.00+00.00%2026-07-09
lockedlocked$00.00+00.00%2026-02-25Find Out Why

1 of 1

Forecast return on equity

Is TARS forecast to generate an efficient return?

Company
88.98%
Industry
15.36%
Market
166.97%
TARS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is TARS forecast to generate an efficient return on assets?

Company
50.48%
Industry
23.16%
TARS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

TARS earnings per share forecast

What is TARS's earnings per share in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
-$0.69
Avg 2 year Forecast
$3.11
Avg 3 year Forecast
$5.28

TARS revenue forecast

What is TARS's revenue in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
$716.3M+18.14%
Avg 2 year Forecast
$924.6M+52.49%
Avg 3 year Forecast
$1.1B+83.73%
TARS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

TARS revenue growth forecast

How is TARS forecast to perform vs Biotechnology companies and vs the US market?

Company
22.61%
Industry
32.4%
Market
13.27%
TARS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
TARS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

TARS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TARS$72.70$93.00+27.92%Strong Buy
MBX$66.33$84.60+27.54%Strong Buy
CLDX$40.38$58.10+43.88%Strong Buy
ARQT$25.08$36.67+46.20%Strong Buy
IMNM$28.52$35.43+24.23%Strong Buy
View Top Biotech Stocks

Tarsus Pharmaceuticals Stock Forecast FAQ

Is Tarsus Pharmaceuticals Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: TARS) stock is to Strong Buy TARS stock.

Out of 5 analysts, 2 (40%) are recommending TARS as a Strong Buy, 3 (60%) are recommending TARS as a Buy, 0 (0%) are recommending TARS as a Hold, 0 (0%) are recommending TARS as a Sell, and 0 (0%) are recommending TARS as a Strong Sell.

If you're new to stock investing, here's how to buy Tarsus Pharmaceuticals stock.

What is TARS's earnings growth forecast for 2026-2028?

(NASDAQ: TARS) Tarsus Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.47%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.28%.

Tarsus Pharmaceuticals's earnings in 2026 is -$46,476,000.On average, 11 Wall Street analysts forecast TARS's earnings for 2026 to be -$30,463,576, with the lowest TARS earnings forecast at -$48,293,237, and the highest TARS earnings forecast at -$18,891,630. On average, 10 Wall Street analysts forecast TARS's earnings for 2027 to be $136,647,261, with the lowest TARS earnings forecast at $71,388,858, and the highest TARS earnings forecast at $199,974,813.

In 2028, TARS is forecast to generate $231,785,597 in earnings, with the lowest earnings forecast at $131,166,275 and the highest earnings forecast at $311,481,506.

What is TARS's revenue growth forecast for 2026-2028?

(NASDAQ: TARS) Tarsus Pharmaceuticals's forecast annual revenue growth rate of 22.61% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.4%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.27%.

Tarsus Pharmaceuticals's revenue in 2026 is $606,331,000.On average, 11 Wall Street analysts forecast TARS's revenue for 2026 to be $31,434,706,525, with the lowest TARS revenue forecast at $29,587,671,223, and the highest TARS revenue forecast at $32,838,523,567. On average, 10 Wall Street analysts forecast TARS's revenue for 2027 to be $40,574,218,102, with the lowest TARS revenue forecast at $36,554,535,668, and the highest TARS revenue forecast at $45,550,549,848.

In 2028, TARS is forecast to generate $48,885,657,544 in revenue, with the lowest revenue forecast at $41,139,869,920 and the highest revenue forecast at $58,408,267,676.

What is TARS's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: TARS) forecast ROA is 50.48%, which is higher than the forecast US Biotechnology industry average of 23.16%.

What is TARS's Price Target?

According to 5 Wall Street analysts that have issued a 1 year TARS price target, the average TARS price target is $93.00, with the highest TARS stock price forecast at $100.00 and the lowest TARS stock price forecast at $88.00.

On average, Wall Street analysts predict that Tarsus Pharmaceuticals's share price could reach $93.00 by Aug 12, 2027. The average Tarsus Pharmaceuticals stock price prediction forecasts a potential upside of 27.92% from the current TARS share price of $72.70.

What is TARS's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: TARS) Tarsus Pharmaceuticals's current Earnings Per Share (EPS) is -$1.08. On average, analysts forecast that TARS's EPS will be -$0.69 for 2026, with the lowest EPS forecast at -$1.10, and the highest EPS forecast at -$0.43. On average, analysts forecast that TARS's EPS will be $3.11 for 2027, with the lowest EPS forecast at $1.63, and the highest EPS forecast at $4.56. In 2028, TARS's EPS is forecast to hit $5.28 (min: $2.99, max: $7.10).

What is TARS's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: TARS) forecast ROE is 88.98%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.